title: Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma.
authors.affiliation: Department of Medicine, Internal Medicine Residency Training Program, University of Colorado School of Medicine, Aurora, Colorado, USA.
authors.forename: Ajay
authors.identifier: http://orcid.org/0000-0001-7261-1335
authors.initials: A
authors.lastname: Major
authors.affiliation: Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado, USA.
authors.forename: Zenggang
authors.initials: Z
authors.lastname: Pan
authors.affiliation: Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA.
authors.forename: Manali
authors.initials: M
authors.lastname: Kamdar
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage; D020794:Receptor Protein-Tyrosine Kinases; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases